Commerzbank Aktiengesellschaft FI Raises Holdings in Eli Lilly and Company (NYSE:LLY)

Commerzbank Aktiengesellschaft FI grew its stake in Eli Lilly and Company (NYSE:LLY) by 10.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 4,254 shares of the company’s stock after buying an additional 389 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Eli Lilly and Company were worth $3,851,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Tidemark LLC acquired a new stake in Eli Lilly and Company during the fourth quarter worth approximately $29,000. Core Wealth Advisors Inc. raised its position in Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares during the last quarter. Lynx Investment Advisory purchased a new stake in Eli Lilly and Company in the 2nd quarter valued at $32,000. Frank Rimerman Advisors LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth $37,000. Finally, St. Johns Investment Management Company LLC grew its position in Eli Lilly and Company by 123.3% during the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after purchasing an additional 37 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 2,052 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the transaction, the insider now owns 98,554,195 shares of the company’s stock, valued at $79,730,343,755. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total transaction of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 2,052 shares of Eli Lilly and Company stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the sale, the insider now directly owns 98,554,195 shares of the company’s stock, valued at approximately $79,730,343,755. The disclosure for this sale can be found here. Insiders have sold 1,214,704 shares of company stock worth $1,066,841,316 over the last ninety days. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $0.57 on Wednesday, hitting $949.40. The company’s stock had a trading volume of 1,966,595 shares, compared to its average volume of 3,098,212. The company has a market capitalization of $902.31 billion, a P/E ratio of 139.10, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41. Eli Lilly and Company has a 52-week low of $516.57 and a 52-week high of $967.00. The firm has a fifty day moving average price of $881.72 and a 200-day moving average price of $810.11. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 0.55%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 76.58%.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Thursday, July 11th. Truist Financial restated a “buy” rating and set a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Jefferies Financial Group raised their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research note on Monday, June 24th. Argus boosted their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research note on Tuesday, May 14th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their price objective for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. Two analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $956.88.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.